Hope Medicine Inc. Announces Positive Phase 2 Results for HMI-115 in Endometriosis Treatment

Hope Medicine Inc., a clinical-stage innovative biopharmaceutical company, announced positive results from an interim analysis of a global Phase 2 study, titled “A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of HMI-115 in Women with Moderate to Severe Endometriosis Associated Pain Over a 12-Week Treatment Period.” HMI-115 is a monoclonal antibody that blocks the prolactin receptor and serves as a first-in-class treatment for endometriosis.

Publish Date: 24-10-2024 Source: Hope Medicine Inc.

Endometriosis, a condition characterized by the abnormal proliferation of endometrial tissue similar to that lining the uterus but occurring outside it, manifests as endometrial implants in ectopic sites. These lesions are commonly found on organs such as the ovaries, Fallopian tubes, uterine surface, bowel, and pelvic cavity membrane (peritoneum), with less frequent occurrences in the vaginal, cervical, and bladder regions. While occasionally found outside the pelvis, endometriosis generally remains confined to the pelvic area. Endometrial implants can lead to complications, but they typically pose no significant harm. The severity of endometriosis is classified into four stages—mild (Stage I), mild (Stage II), moderate (Stage III), and severe (Stage IV)—based on criteria including the number, location, and depth of implants and the presence of filmy or dense adhesions. Another staging system primarily assesses the severity of pelvic pain. However, a more reliable staging method is actively sought due to substantial intra- and inter-observer variability in these systems. The U.S. Food and Drug Administration (FDA) has approved several medications for managing endometriosis, including Lupron Depot (leuprolide acetate for depot suspension), Myfembree (relugolix, estradiol, and norethindrone acetate), Orilissa (elagolix), and Zoladex (goserelin acetate implant).

Globally, endometriosis affects approximately 10% (190 million) of women and girls of reproductive age.

However, the current Endometriosis treatment market share, market uptake, and attribute analysis concerning the most potential emerging therapies (Leuprolide, Relugolix, 99mTc-maraciclatide, etc..) has been provided under the market outlook section of the study covering 8 MM countries; The United States, EU5 (Germany, Spain, France, Italy, UK) Japan and China.

In terms of pharmacologic therapies, several pharmaceutical products are being approved and under different phases of development for the Endometriosis treatment. The key companies in the advanced development stage are Enteris BioPharma Inc., Myovant Sciences GmbH, Serac Healthcare Limited, etc..

Based on solid domain and business knowledge, Thelansis Knowledge Partners has published the market outlook forecast report on Endometriosis to provide a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2023 to 2033.

About Thelansis:

Thelansis specializes in pharmaceutical market outlook and market forecast reports. We published reports across the therapeutic area, including rare / ultra-rare and mainstream indications. Over the period, we have built a robust repository of 6,000+ Bio-pharma reports that cover Epidemiology studies and Market forecasting based on the KOL opinions.

Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the primary focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.